VentriPoint Diagnostics Ltd. ("VentriPoint" or the "Corporation") (TSX
VENTURE:VPT) is pleased to announce that the manuscript entitled, "Accuracy of
Knowledge Based Reconstruction (KBR) for Measurement of Right Ventricular Volume
and Function in Patients with Tetralogy of Fallot" has been accepted for
publication in the American Journal of Cardiology. The study will be published
in the journal's April, 2010 issue. 


This study demonstrated the accuracy and reproducibility of the KBR method which
enables physicians to monitor their patients' hearts from ultrasound or magnetic
resonance images. The results of the study were presented at the Scientific
Sessions of the American Heart Association in November, 2008 by the lead author,
Dr. Florence Sheehan, a cardiologist and professor at the University of
Washington. She led a multinational team of investigators in collecting and
analyzing patient data for the study. 


The KBR method was successfully applied for patients with the most common type
of congenital heart disease (CHD) causing a "blue baby" at birth. Studies are in
progress at VentriPoint to validate KBR for the other types of CHD. The
investigative team has enlarged to now include sites in Canada, the UK, the
Netherlands, and Switzerland in addition to the U.S., indicating the intense
clinical need everywhere for VentriPoint's service. 


"The acceptance of this manuscript by such an esteemed authority as the American
Journal of Cardiology represents a validation of our efforts to introduce a much
needed tool for monitoring right ventricular volume and function from 2D
Ultrasounds images," stated Joe Ashley, President & CEO of the Corporation. "We
continue to pursue the European and U.S. regulatory authority and the requisite
capital to commercialize our exceptionally accurate system to health
professionals as a tool for their diagnosis and treatment of cardiovascular
disease. Rapid and accurate right ventricle measurements is essential for
patient assessment."


There are greater than 1 million American adults and 800,000 children with CHD,
according to the American Heart Association and the Adult Congenital Heart
Association. With 36,000 CHD births every year, the number of CHD patients
requiring serial RV monitoring is rising due to their longer survival as a
result of extremely successful diagnostic and treatment strategies developed and
employed over the past 40 years. VentriPoint also plans to extend its service to
patients with other types of lung and heart diseases, bringing the total
estimated market for the VentriPoint Medical System to exceed $5 Billion
worldwide. 


About VentriPoint Diagnostics Ltd. 

VentriPoint creates diagnostic tools to monitor patients with heart disease -
the number one cause of death in developed countries. By using images produced
from existing medical imaging systems, the VentriPoint Medical System ("VMS")
generates critical heart measurements in a rapid, accurate and inexpensive
manner not currently available. Health Canada has granted licensed approval for
the VMS breakthrough diagnostic tool which is based upon technology received by
VentriPoint through its exclusive technology license with the University of
Washington. The VMS, together with its associated online service, is being
developed for a variety of heart related disease states, including congenital
heart disease and pulmonary hypertension.


To receive press release, please email chris@chfir.com and mention VentriPoint
in the Subject line.


FORWARD-LOOKING STATEMENTS: The statements made in this press release that are
not historical facts contain forward-looking information that involves risk and
uncertainties. All statements, other than statements of historical facts, which
address VentriPoint's expectations, should be considered forward-looking
statements. Such statements are based on management's exercise of business
judgment as well as assumptions made by and information currently available to
management. When used in this document, the words "may", "will", "anticipate",
"believe", "estimate", "expect", "intend" and words of similar import, are
intended to identify any forward-looking statements. You should not place undue
reliance on these forward-looking statements. These statements reflect a current
view of future events and are subject to certain risks and uncertainties as
contained in the Corporation's filings with Canadian securities regulatory
authorities. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results could differ
materially from those anticipated in these forward-looking statements. The
Corporation undertakes no obligation, and does not intend, to update, revise or
otherwise publicly release any revisions to these forward-looking statements to
reflect events or circumstances after the date hereof, or to reflect the
occurrence of any unanticipated events. Although management believes that
expectations are based on reasonable assumptions, no assurance can be given that
these expectations will materialize.
Vortex Metals (TSXV:VMS)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Vortex Metals Charts.
Vortex Metals (TSXV:VMS)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Vortex Metals Charts.